PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30482227-11 2018 RESULTS: IFN-alpha down-regulated the cyclooxygenase-2 (COX-2) expression in bladder cancer cells through the inhibition of TPL2/NF-kappaB pathway; IFN-alpha also inhibited COX-2 expression by suppressing cAMP signaling through TPL2-ERK mediated PDE4D activity. Cyclic AMP 205-209 interferon alpha 1 Homo sapiens 9-18 30482227-11 2018 RESULTS: IFN-alpha down-regulated the cyclooxygenase-2 (COX-2) expression in bladder cancer cells through the inhibition of TPL2/NF-kappaB pathway; IFN-alpha also inhibited COX-2 expression by suppressing cAMP signaling through TPL2-ERK mediated PDE4D activity. Cyclic AMP 205-209 interferon alpha 1 Homo sapiens 148-157 30482227-12 2018 Reduction of the intracellular cAMP level by PDE4D potentiated the antitumor effect of IFN-alpha against bladder cancer in vitro and in vivo. Cyclic AMP 31-35 interferon alpha 1 Homo sapiens 87-96 30482227-15 2018 The antitumor effects of IFN-alpha and MEK inhibition also depend on the PDE4D-mediated cAMP level in bladder cancer cells. Cyclic AMP 88-92 interferon alpha 1 Homo sapiens 25-34 30482227-16 2018 Suppression of the TPL2 phosphorylation and intracellular cAMP level may be possible therapeutic strategies for enhancing the effectiveness of IFN-alpha and MEK inhibitors in bladder cancer treatment. Cyclic AMP 58-62 interferon alpha 1 Homo sapiens 143-152